P&G transfers Vicks medicated cough drop business in Japan to Taisho Pharmaceutical in deal announced May 14. Under agreement, Taisho obtains perpetual license rights to trademark, formula of Vicks Medicated Drops, as well as rights to all product sales; P&G will continue as contract manufacturer "for the foreseeable future," Taisho says. Firm also becomes exclusive sales agent of VicksVapoRub in Japan, although P&G will continue to manufacture the product. P&G says deal is part of its strategic decision to invest in larger markets; aside from Japan, Vicks Medicated Drops are only sold in India, Indonesia, Singapore and are not among top-selling Vicks offerings...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Country recommends eights new drugs for approval, including six for rare diseases, and also announces macroeconomic policy the pharma industry says would enable some reimbursement prices to be raised.
The 14 July deadline for the Citeline Japan Awards 2025 in Tokyo is approaching fast, so here's a reminder to take a look at the categories and criteria and be sure to get your submissions in by this date. Sponsorship opportunities and tables for the event are also available.
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.
Japan is cutting more drug reimbursement prices following cost effectiveness analysis and is applying the methodology to a new group of products including Wegovy and Leqembi.
Country recommends eights new drugs for approval, including six for rare diseases, and also announces macroeconomic policy the pharma industry says would enable some reimbursement prices to be raised.
The 14 July deadline for the Citeline Japan Awards 2025 in Tokyo is approaching fast, so here's a reminder to take a look at the categories and criteria and be sure to get your submissions in by this date. Sponsorship opportunities and tables for the event are also available.
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.
